IP Library Granted Patent US 9,682,927
Granted Patent B2
US 9,682,927 · App. 15/170,848 · Granted Jun 20, 2017

Compositions, methods, and systems for the synthesis and use of imaging agents

Inventors: Ajay Purohit (Sudbury, MA); Pedro Benites (Watertown, MA); Edward H. Cheesman (Lunenburg, MA); Richard R. Cesati (Pepperell, MA); Richard J. Looby (Reading, MA); Heike S. Radeke (South Grafton, MA)
Assignee: Lantheus Medical Imaging, Inc.
C07C303/30A61K51/04A61K51/0406C07B59/001C07C53/06C07C53/10C07C53/18C07C63/08C07C213/02C07C217/58C07C255/54C07C277/08C07C279/10C07C279/24C07C303/28C07C309/04C07C309/30C07C309/65C07C309/66C07C309/73A61K51/00C07B2200/05C07C277/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,682,927
App. No.
15/170,848
Granted
Jun 20, 2017
Kind
B2
Abstract

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Claims (73)

1. A method, comprising:

reacting a compound comprising formula (II):

or a salt, free base, or combination thereof, under suitable conditions comprising exposing the compound of formula (II) to an acid to form a compound comprising formula (IV):

or a salt, free base, or combination thereof, wherein:

R 1 is alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, heterocyclyl, or haloalkyl, each optionally substituted;

each R 2 can be the same or different and is hydrogen or a nitrogen-protecting group, provided at least one R 2 is not hydrogen;

R 3 , R 4 , R 5 , and R 6 can be the same or different and are individually hydrogen, C 1 -C 6 alkyl, heteroalkyl, halide, —OR 7 , —SR 7 , —N(R 7 ) 2 , or —C(═O)R 8 , each optionally substituted;

each R 7 can be the same or different and is hydrogen, alkyl, heteroalkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted;

each R 8 can be the same or different and is hydrogen, alkyl, heteroalkyl, cycloalkyl, haloalkyl, heterocyclyl, aryl, heteroaryl, —OH, alkoxy, —NH 2 , alkylamino, —SH, or alkylthiol, each optionally substituted;

m is an integer between 1 and 12, inclusive; and

n is an integer between 1 and 4, inclusive.

2. A method, comprising:

reacting a compound comprising formula (IV):

or a salt, free base, or combination thereof, under suitable conditions suitable to form a compound comprising formula (V):

or a salt, free base, or combination thereof, wherein:

R 1 is alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, or haloalkyl, each optionally substituted;

R 3 , R 4 , R 5 , and R 6 can be the same or different and are individually hydrogen, C 1 -C 6 alkyl, heteroalkyl, halide, —OR 7 , —SR 7 , —N(R 7 ) 2 , or —C(═O)R 8 , each optionally substituted;

each R 7 can be the same or different and is hydrogen, alkyl, heteroalkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted;

each R 8 can be the same or different and is hydrogen, alkyl, heteroalkyl, cycloalkyl, haloalkyl, heterocyclyl, aryl, heteroaryl, —OH, alkoxy, —NH 2 , alkylamino, —SH, or alkylthiol, each optionally substituted;

m is an integer between 1 and 12, inclusive; and

n is an integer between 1 and 4, inclusive,

wherein the step of reacting comprises exposing a compound comprising formula (IV) to a source of fluoride, wherein the source of fluoride is isotopically enriched with 18 F.

3. The method of claim 2 , wherein the compound of formula (IV) comprises a compound of formula (III):

wherein X ⊖ is a counter anion.

4. The method of claim 3 , wherein X ⊖ is halide, phosphate, sulfate, trifluoroacetate, tolunesulfonate, acetate, formate, citrate, ascorbate, mesylate (methanesulfonate), or benzoate.

5. The method of claim 1 , wherein the compound of formula (II) comprises a compound of formula:

or a salt, free base, or combination thereof.

6. The method of claim 5 , wherein at least one R 2 is t-butyloxycarbonyl.

7. The method of claim 1 , wherein the compound of formula (II) comprises the formula:

or a salt, free base, or combination thereof.

8. The method of claim 2 , wherein the compound of formula (IV) comprises the formula:

or a salt, free base, or combination thereof.

9. The method of claim 2 , wherein m is 3.

10. The method of claim 2 , wherein R 1 is:

(a) C 1 -C 6 alkyl, haloalkyl, or aryl;

(b) methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl, or hexyl;

(c) haloalkyl;

(d) CF 3 ;

(e) phenyl, optionally substituted; or

(f) 4-CH 3 C 6 H 4 , 2,4,6-(CH 3 ) 3 C 6 H 2 , or C 6 H 4 X, wherein X is halide.

11. The method of claim 1 , wherein the acid is hydrochloric acid, formic acid, sulfuric acid, benzoic acid, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, phosphoric acid, or methanesulfonic acid.

12. A method, comprising:

reacting a compound comprising formula (IV):

or a salt, free base, or combination thereof, under suitable conditions to form a compound comprising formula (V):

or a salt, free base, or combination thereof, wherein:

R 1 is alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, or haloalkyl, each optionally substituted;

R 3 , R 4 , R 5 , and R 6 can be the same or different and are individually hydrogen, C 1 -C 6 alkyl, heteroalkyl, halide, —OR 7 , —SR 7 , —N(R 7 ) 2 , or —C(═O)R 8 , each optionally substituted;

each R 7 can be the same or different and is hydrogen, alkyl, heteroalkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted;

each R 8 can be the same or different and is hydrogen, alkyl, heteroalkyl, cycloalkyl, haloalkyl, heterocyclyl, aryl, heteroaryl, —OH, alkoxy, —NH 2 , alkylamino, —SH, or alkylthiol, each optionally substituted;

m is an integer between 1 and 12, inclusive; and

n is an integer between 1 and 4, inclusive,

wherein the compound comprising formula (IV) is provided as a solution in a solvent.

13. The method of claim 2 , wherein the suitable conditions comprise reacting at or above room temperature.

14. The method of claim 2 , wherein the suitable conditions comprise reacting at a temperature of about 110° C. for a period of 20 minutes or less.

15. The method of claim 2 , wherein the suitable conditions comprise a solution pH of between about 10 and about 13.

16. The method of claim 1 , wherein the suitable conditions comprise a solution pH equal to or less than 3.

17. The method of claim 2 , wherein the compound comprising formula (V) is isolated using column chromatography.

18. The method of claim 12 , wherein the step of reacting comprises exposing a compound comprising formula (IV) to a source of fluoride.

19. The method of claim 18 , wherein the source of fluoride is isotopically enriched with 18 F.

20. The method of claim 2 , wherein the suitable conditions further comprise exposing a compound comprising formula (IV) to a source of fluoride in the presence of an ammonium salt or a bicarbonate salt.

21. The method of claim 20 , wherein the molar ratio of ammonium salt or bicarbonate salt to the compound of formula (IV) is less than or equal to about 5:1.

22. The method of claim 21 , wherein the bicarbonate salt is a tetraalkylammonium bicarbonate.

23. The method of claim 21 , wherein the ammonium salt or the bicarbonate salt comprises the formula:

R 4 NHCO 3 ,

wherein R 4 is alkyl.

24. The method of claim 2 , wherein the compound comprising formula (V) comprises a compound of formula:

or a salt, free base, or combination thereof.

25. The method of claim 2 , wherein the compound comprising formula (V) comprises a compound of formula:

wherein X ⊖ is a counter anion.

26. The method of claim 25 , wherein X ⊖ is ascorbate.

27. The method of claim 25 , wherein X ⊖ is formate.

28. The method of claim 12 , wherein the compound comprising formula (V) comprises a compound of formula:

or a salt, free base, or combination thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 062047/0925 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Jun 28, 2019
From: LANTHEUS MEDICAL IMAGING, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 049628/0001 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2019
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 049623/0123 →
SECURITY AGREEMENT Recorded Mar 31, 2017
From: LANTHEUS MEDICAL IMAGING, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 042118/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2016
From: PUROHIT, AJAY; BENITES, PEDRO; CHEESMAN, EDWARD H.; LAZEWATSKY, JOEL; LEE, VERONICA; CESATI, RICHARD R., III; LOOBY, RICHARD J.; RADEKE, HEIKE S.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 040194/0073 →
Continuity (5)
Division 13697287
Provisional Application 61405571 · Oct 21, 2010
Provisional Application 61405524 · Oct 21, 2010
Provisional Application 61333618 · May 11, 2010
Related Publication 20160362362A1 · Dec 15, 2016